Targets › HEXA
1 program from 1 company in 1 trial: 1 Phase 1; Metabolic and endocrine; next expected readout Mar 2027.
Hydrolyzes the non-reducing end N-acetyl-D-hexosamine and/or sulfated N-acetyl-D-hexosamine of glycoconjugates, such as the oligosaccharide moieties from proteins and neutral glycolipids, or from certain mucopolysaccharides. The isozyme S is as active as the isozyme A on the anionic bis-sulfated glycans, the chondroitin-6-sulfate trisaccharide (C6S-3), and the dermatan sulfate pentasaccharide, and the sulfated…. (UniProt, P06865)
Open in Phaseline: the race on HEXA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Dr. Anupam Sehgal | TSHA-101 AAV9 viral vector containing HEXA and HEXB genes | HEXA, HEXB | Phase 1 | Infantile GM2 Gangliosidosis (Disorder) | Mar 2027 |
Infantile GM2 Gangliosidosis (Disorder) (1)
protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.